USP6 Gene (Ubiquitin Specific Peptidase 6)

A key oncogene involved in aneurysmal bone cyst formation and other neoplasms

Gene Information Card

Symbol USP6
Full Name Ubiquitin Specific Peptidase 6
Gene Type Protein coding
Chromosomal Location 17p13.2
NCBI Gene ID 9098 ncbi.nlm.nih.gov/gene/9098
Ensembl ID ENSG00000129204
UniProt ID P35125
OMIM ID 604334
HGNC ID 12612
Aliases Tre2, TRE17, USP6 (ubiquitin specific peptidase 6)

Description

USP6 (Ubiquitin Specific Peptidase 6) encodes a deubiquitinating enzyme that removes ubiquitin from target proteins, thereby regulating protein stability and signaling pathways. It is a well-established oncogene, frequently activated by chromosomal rearrangements that lead to its overexpression. USP6 fusions are a hallmark of primary aneurysmal bone cyst (ABC) and nodular fasciitis, and are also found in other benign and malignant neoplasms.

Disease Associations

Disease category Pathophysiological mechanism Genomic evidence
Aneurysmal Bone Cyst (ABC) USP6 gene fusions (e.g., CDH11-USP6) lead to USP6 overexpression, driving osteoclastogenesis and tumor formation. NCBI Gene, OMIM, ClinVar
Nodular Fasciitis USP6 rearrangements (e.g., MYH9-USP6) cause USP6 overexpression, promoting myofibroblastic proliferation. NCBI Gene, OMIM, ClinVar
Myositis Ossificans USP6 fusions are identified in a subset of cases, suggesting a similar mechanism to ABC. NCBI Gene, OMIM
Fibroma of Tendon Sheath USP6 rearrangements have been reported, linking it to benign fibrous tumors. NCBI Gene, OMIM

Expression Profile

Tissue Expression
Tissue nTPM level
Bone marrow 0.0 Not detected
Lymph node 0.0 Not detected
Spleen 0.0 Not detected
Testis 0.0 Not detected
Thyroid 0.0 Not detected
Adipose tissue 0.0 Not detected
Brain 0.0 Not detected
Heart 0.0 Not detected
Kidney 0.0 Not detected
Liver 0.0 Not detected
Lung 0.0 Not detected
Pancreas 0.0 Not detected
Prostate 0.0 Not detected
Skin 0.0 Not detected
Small intestine 0.0 Not detected
Stomach 0.0 Not detected
Colon 0.0 Not detected
Esophagus 0.0 Not detected
Ovary 0.0 Not detected
Breast 0.0 Not detected
Cervix 0.0 Not detected
Endometrium 0.0 Not detected
Fallopian tube 0.0 Not detected
Vagina 0.0 Not detected
Placenta 0.0 Not detected
Adrenal gland 0.0 Not detected
Pituitary gland 0.0 Not detected
Salivary gland 0.0 Not detected
Skeletal muscle 0.0 Not detected
Smooth muscle 0.0 Not detected
Tonsil 0.0 Not detected
Urinary bladder 0.0 Not detected
Cell Line Expression
Cell Line nTPM Notes
HeLa 0.0 Not detected
HEK 293 0.0 Not detected
K562 0.0 Not detected
MCF7 0.0 Not detected
A549 0.0 Not detected
HepG2 0.0 Not detected
SH-SY5Y 0.0 Not detected
THP-1 0.0 Not detected
U2OS 0.0 Not detected
Jurkat 0.0 Not detected
Data source:Human Protein Atlas(proteinatlas.org)

Mutations & Variants

Hotspot Mutations
Variant Type Frequency Functional Description
CDH11-USP6 fusion Gene fusion Common in ABC Overexpression of USP6, leading to oncogenic signaling
MYH9-USP6 fusion Gene fusion Common in nodular fasciitis Overexpression of USP6, promoting myofibroblastic proliferation
COL1A1-USP6 fusion Gene fusion Rare Overexpression of USP6
TRAP150-USP6 fusion Gene fusion Rare Overexpression of USP6
USP6 amplification Copy number gain Rare Increased USP6 expression
Mutation functional classification

Loss of Function (LOF)

Not applicable; USP6 is an oncogene activated by overexpression, not loss-of-function.

Gain of Function (GOF)

USP6 gene fusions and amplifications result in gain-of-function through overexpression of the deubiquitinase, leading to increased cell proliferation and tumorigenesis.

Dominant Negative (DN)

Not reported for USP6.

Pathways

• Ubiquitin-proteasome system
• RANKL signaling (osteoclastogenesis)
• MAPK signaling (via USP6-mediated stabilization of signaling intermediates)

Protein Summary

USP6 (Ubiquitin Specific Peptidase 6) is a 1406-amino acid deubiquitinating enzyme that cleaves ubiquitin from target proteins, thereby preventing their proteasomal degradation. It contains an N-terminal Tre2 domain and a C-terminal catalytic USP domain. USP6 is normally expressed at very low levels in most adult tissues, but is highly overexpressed in certain tumors due to promoter swapping from gene fusions. Overexpressed USP6 stabilizes proteins involved in cell growth and osteoclast differentiation, such as MMP9 and NFATc1, contributing to the pathogenesis of aneurysmal bone cyst and nodular fasciitis.

Related Products

Product name Cat.No. Species Gene ID
USP6 Knockout HEK293 Cell Line EDJ-KQ6459 Human 9098 Details Get a Quote
USP6NL Knockout HEK293 Cell Line EDJ-KQ6709 Human 9712 Details Get a Quote
USP6NL Knockout A-549 Cell Line EDJ-KQ31074 Human 9712 Details Get a Quote
USP6NL Knockout HCT 116 Cell Line EDJ-KQ31075 Human 9712 Details Get a Quote
USP6NL Knockout HeLa Cell Line EDJ-KQ31076 Human 9712 Details Get a Quote
USP6 Knockout HeLa Cell Line EDJ-KQ55085 Human 9098 Details Get a Quote
USP6 Knockout A-549 Cell Line EDJ-KQ63564 Human 9098 Details Get a Quote
USP6 Knockout HCT 116 Cell Line EDJ-KQ72032 Human 9098 Details Get a Quote

Biological Process

Gene Expression and Regulation: A Complete Technical Map from Mechanism to Validated Cell Models

Promoters, Enhancers and 3D Genome Organization: How to Validate Regulatory Relationships with Editing and Interference Tools

Enhancer–Gene Pair Validation: A Complete Technical Roadmap from Candidate Element to Publishable Evidence

CRISPR Deletion vs CRISPRi for Regulatory Elements: Choosing by Evidence Requirement

Building Reporter Cell Lines for Quantitative Regulatory Readouts

TAD Boundaries and Insulators: What They Constrain and What They Do Not Prove

Super-Enhancers and Cell Identity: Design Strategies for Functional Validation

Validating Transcription Factor Binding Sites: From ChIP Peaks to Functional Evidence

From GWAS Signal to Causal Variant: Functional Validation of Non-Coding Risk Loci

Enhancer Redundancy and Shadow Enhancers: Designing Controls That Catch Compensation

Core Promoter Elements: Dissecting Initiator, TATA and CpG-Island Promoters

Single-Cell Multi-Omics for Mapping Regulatory Elements in Heterogeneous Tissues

How Many Candidate Enhancers Can a Single CRISPRi Screen Test?

What Fragment Size Should Be Deleted When Removing an Enhancer?

How to Design sgRNAs for Enhancer Deletion

What Effect Size Counts as Biologically Meaningful in Enhancer Studies?

What Controls Are Required for a Regulatory Element Knockout?

How to Confirm a TAD Boundary Is Functional

Can ATAC-seq Alone Identify Functional Enhancers?

What Is a Shadow Enhancer, and Why Does It Break Your Screen?

How to Report Negative Results in Regulatory Element Studies

Distance Window or TAD Boundary: Which Constraint Matters More?

DNA Methylation, Histone Marks and Chromatin State: Selecting and Validating Epigenome-Editing Tools

CRISPRoff, dCas9-TET and dCas9-p300: A Practical Comparison for Targeted Epigenetic Editing

How Long Does Epigenetic Silencing Last? Stability, Inheritance and Reversibility

DNMT and TET Knockout Cell Lines: What Phenotypes to Expect and How to Verify Them

Reading Chromatin Accessibility: From ATAC-seq Peaks to Functional Hypotheses

Histone Modification Writers, Readers and Erasers: A Knockout Map

Assessing Off-Target Effects in Epigenetic Editing

Single-Cell Epigenomics: scATAC-seq and scChIP-seq in Development and Disease

Spatial Epigenomics: Mapping Modifications In Situ

Epigenetic Clocks and cfDNA Methylation as Biomarkers

Imprinting and Parent-of-Origin Expression: Why Allele-Specific Regulation Matters

What Is CRISPRoff and How Does It Differ From dCas9-KRAB?

How Stable Is Epigenetic Silencing Across Cell Divisions?

Which Cell Line Is Best for Studying DNA Methylation?

How to Validate a DNMT1 Knockout Clone

What Is a Differentially Methylated Region (DMR)?

Do Epigenetic Edits Create Off-Target Methylation Changes?

How to Link ATAC-seq Changes to Gene Expression Causality

What Is Histone Lactylation and Why Does It Matter?

How to Design a Single-Cell ATAC-seq Experiment

Can Epigenetic Editing Restore a Silenced Gene?

lncRNA, miRNA and RNA Modification: A Complete Path from Function Prediction to Phenotype Validation

Why lncRNA Knockouts Often Show No Phenotype — and How to Design Around It

lncRNA Functional Validation: Knockout vs Knockdown vs Antisense Oligonucleotides

m6A Writers, Readers and Erasers: Mapping and Testing RNA Modification Function

miRNA–Target Validation: Evidence Beyond Luciferase Reporter Assays

RNA-Binding Protein Screens: Design, Readouts and Hit Prioritization

Alternative Splicing Regulation: Isoform-Level Validation Strategies

Circular RNA Biology: Detection, Function and Experimental Pitfalls

RNA Localization and the Spatial Regulation of Translation

Why Does an lncRNA Knockout Often Show No Phenotype?

Knockdown vs Knockout for lncRNA: Which Is More Informative?

How Long a Fragment Should Be Deleted for an lncRNA Knockout?

Which m6A Antibody Should I Use for MeRIP-seq?

What Is the Difference Between RIP-seq and CLIP-seq?

How to Validate a miRNA Target Without a Luciferase Assay

How Many Isoforms Must an Alternative Splicing Study Cover?

Is Circular RNA Detection Reliable Across Platforms?

How to Verify RNA Localization Experimentally

What Proportion of Annotated lncRNAs Are Functional?

CRISPR Knockout, Knock-In, Activation and Screening: A Strategy Matrix for Regulatory Research

Knockout, CRISPRi or Base Editing? A Six-Dimension Decision Matrix

Genome-Wide CRISPR Screening: Library Coverage, MOI and Readout Design

Perturb-seq and Single-Cell Screens: Linking Perturbation to Transcriptional Programs

Essential Genes and Lethal Phenotypes: How to Study What You Cannot Knock Out

Base Editing and Prime Editing in Regulatory Research: When Precision Beats Deletion

Quantifying Editing Efficiency and Off-Target Events: A Practical Framework

Choosing a Cas9 Variant and Delivery Format for Your Cell Type

Multiplex Editing and Temporal Control of Gene Regulation

How Much Library Coverage Is Enough for a Genome-Wide Screen?

What MOI Should I Use for a Lentiviral CRISPR Library?

How to Screen a Non-Proliferative Phenotype

How to Study an Essential Gene with CRISPR

What Is the Difference Between Base Editing and Prime Editing?

How to Measure Knockout Efficiency in a Cell Pool

How to Design a Multiplex Knockout Experiment

Which Cas9 Variant Works Best for AAV Delivery?

What Is a Safe-Harbor Locus for Knock-In?

How Many Clones Must Be Screened to Confirm a Homozygous Knockout?

From Pathway to Model: Validation Paradigms in Cancer, Neuro, Immune and Metabolic Research

Oncogene Dependency and Synthetic Lethality: Building the Right Validation Model

Enhancer Dysregulation in Neurodegeneration: Lessons from Glial and Neuronal Models

CAR-T and ADCC Target Validation: Engineering Immune Cell Lines for Functional Assays

Hippo, WNT and PI3K: Validating Pathway Nodes with Knockout Cell Lines

Drug Target Validation: A Standardized Workflow from Hit to Model

Metabolic Pathway Enzymes: Building Loss-of-Function Models

Gene Editing in iPSC and Organoids: Constraints, Timelines and Readouts

Disease-Associated Non-Coding Variants: From Risk Locus to Cellular Phenotype

How to Validate Pathway Activation After a Knockout

How Long Does iPSC Gene Editing Take?

How to Edit Organoids Without Disrupting Their Structure

Which Cell Line Models ADCC Most Reliably?

How to Build a Synthetic Lethality Screen

What Is a Good Model for Enhancer Dysregulation in Neurons?

How to Validate a Drug Target Before Committing to a Programme

Why Does My Knockout Cell Line Lose the Phenotype After Passaging?

How to Choose Between Human and Mouse Cell Models

What QC Documentation Should Accompany a Custom Cell Line?

Gene Knockout Feasibility Self-Assessment: Ten Constraints That Decide the Project

Pathway-to-Model Reference Chart: Key Genes × Recommended Cell Models

Working with Hard-to-Transfect Cells: A Delivery Strategy Guide

How We Validate Knockout Clones: PCR, Sanger and Western Blot in Combination

Custom Knockout Cell Line Service: Strategy Design, Single-Cell Cloning and Triple Validation

Stable dCas9-KRAB and Cas9 Expression Cell Lines

Knock-In Reporter Cell Lines for Regulatory Readouts

Genome-Wide CRISPR Library Screening Service

Services Comparison: In-House vs CRO vs Off-the-Shelf Cell Lines

Epigenetic Editing Enters the Clinic: What It Means for Research Models

AI Sequence Models in Regulatory Genomics: Hype, Reality and Where They Help

Live-Cell Imaging Rewrites the Rules of Transcriptional Regulation

Spatial and Single-Cell Multi-Omics: The Next Validation Frontier

From CRISPR Screens to Programmable Medicine: A Five-Year Outlook

Contact Us
*
*
*
How did you hear about us: